

Special Issue

Zika Virus and Immune Response

Message from the Guest Editors

The recent explosive outbreak of Zika virus (ZIKV) in the Americas in 2015–2016 revealed the unexpected association of ZIKV infection with serious neurodevelopmental disorders in unborn infants, now collectively known as ZIKV congenital syndrome (ZCS). For this Special Issue we encourage the submission of manuscripts addressing both innate and cellular immune responses towards ZIKV and mechanisms employed by the virus to evade these immune responses. We also encourage manuscripts addressing translational efforts towards development and testing of prophylactic vaccines and immunotherapeutics against ZIKV. Ultimately, an improved understanding of immune responses towards ZIKV and exploitation of this understanding will enable development of urgently required prophylactic and therapeutic interventions that are targeted towards ZIKV.

Guest Editors

Dr. Nicholas Eyre

College of Medicine & Public Health, Flinders University, Bedford Park, SA 5042, Australia

Dr. Natalie Prow

Clinical & Health Sciences, University of South Australia, Adelaide, SA 5001, Australia

Deadline for manuscript submissions

closed (15 February 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/52665

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).